Artiva Biotherapeutics (NASDAQ:ARTV) is a clinical-stage biotechnology company focused on the development of natural killer (NK) cell-based therapies for the treatment of cancer. Leveraging proprietary engineering platforms, Artiva designs both invariant natural killer T (iNKT) cells and allogeneic NK cells to enhance anti-tumor activity. Its pipeline includes multiple product candidates targeting hematologic malignancies and solid tumors, with programs advancing through preclinical development and into early-phase clinical trials in the United States, Europe and Australia.
The company’s core technology platforms enable precise genome editing to optimize cell persistence, tumor trafficking and safety profile. Artiva’s iNKT platform harnesses the dual features of NK cells and T cells, while its allogeneic NK cell programs incorporate chimeric antigen receptors (CARs) and cytokine expression cassettes to bolster cytotoxicity against tumor cells. In addition to monotherapy approaches, the company is exploring combination regimens with monoclonal antibodies and immune checkpoint inhibitors to address treatment-resistant cancers.
Founded in 2016 and headquartered in Hayward, California, Artiva maintains research and development operations in both North America and Europe. The company emerged from collaborations among leading immunology and cell therapy researchers and has built a dedicated manufacturing network to support scalable, off-the-shelf cell therapy production. Over the past several years, Artiva has expanded its footprint through strategic partnerships and licensing agreements aimed at accelerating clinical progress and broadening market access.
Artiva is led by a seasoned executive team with deep expertise across biopharmaceutical R&D, manufacturing and commercialization. The leadership roster includes veterans of leading immuno-oncology companies, bringing experience in clinical development, regulatory strategy and global operations. Under this guidance, Artiva aims to advance its cell therapy candidates through pivotal trials and deliver innovative treatment options to patients with high-unmet-need cancers.
